Prime Medicine prices $140M stock offering to fund gene-editing pipeline
What's the deal? Prime Medicine (Nasdaq: PRME) priced a follow-on public offering to raise $140 million, selling 19.2 million shares at $6.25 each. The Cambridge, Massachusetts gene-editing biotech scaled up its initial $125 million target.
Who's involved? Jefferies, TD Cowen, and Goldman SachsDealroom has a profile for this one. Try Dealroom → are joint book-running managers, with OppenheimerDealroom has a profile for this one. Try Dealroom → and LifeSci CapitalDealroom has a profile for this one. Try Dealroom → as passive bookrunners. Prime Medicine also granted underwriters a 30-day option to buy up to $18.75 million in additional shares.
What's the endgame? Prime Medicine is developing one-time gene-editing therapies using its Prime Editing platform, which aims to correct DNA mutations without breaking the double helix. It is advancing Wilson disease and AATD programs toward trials, with initial data expected in 2027.
Why now? The raise follows a $144.2 million share sale in August 2025, which—along with Cystic Fibrosis FoundationDealroom has a profile for this one. Try Dealroom → funding—was expected to fund operations into 2027. By June 2026, however, cash had fallen to $108.8 million, and the company said it still expected to need more capital.
What could go wrong? The offering dilutes existing shareholders, and Prime Medicine's key in-vivo programs remain years from showing human results. Final proceeds depend on market conditions.
The signal: The timing underscores the funding pressure on clinical-stage biotechs burning cash ahead of trial data. For Prime Medicine, backed by gene-editing pioneers David Liu and Andrew Anzalone, each raise buys more runway to prove its platform works in humans.
Read more: marketscreener.com
Image credit: Generated with Gemini
